A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma [0.03%]
针对复发或难治性大B细胞淋巴瘤患者中注射用Mosunetuzumab与Polatuzumab Vedotin联合用药对比利妥昔单抗联合Polatuzumab Vedotin的II期随机研究
Julio C Chavez,Mariana Bastos-Oreiro,Catherine Diefenbach et al.
Julio C Chavez et al.
Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase I...
Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome [0.03%]
获得性血管性血友病的临床和实验室特征分析
Alessandro Ciavarella,Luciano Baronciani,Omid Seidizadeh et al.
Alessandro Ciavarella et al.
Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associate...
CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib-Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET-CT [0.03%]
Orelabrutinib治疗原发中枢神经系统淋巴瘤脑脊液ctDNA分子转阴的预后价值及与PET-CT影像学对比研究
Lixia Sheng,Huijie Hu,Yanli Lai et al.
Lixia Sheng et al.
This prospective biomarker study evaluated serial CSF ctDNA monitoring in newly diagnosed PCNSL treated with R-MO induction therapy. Mid-treatment ctDNA clearance was significantly associated with complete response and superior progression-...
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents [0.03%]
VEXAS综合征的治疗结局：allo-HSCT和低甲基化药物的多中心比较队列研究
Saubia Fathima,Margaret Mei-Kay Wong,Jesus Gonzalez-Lugo et al.
Saubia Fathima et al.
Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patien...
Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia [0.03%]
exonuclegene自体造血干细胞移植后输血依赖型β-地中海贫血无效红细胞生成的纠正和铁稳态的正常化
Sujit Sheth,Selim Corbacioglu,Josu de la Fuente et al.
Sujit Sheth et al.
Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo, CRISPR-Cas9 gene edited cell therapy approved for patients with transfusion dependent β-thalassemia (TDT) aged 12-35 years. In a Phase 3 study (CLIMB THAL-111), exa-cel treatment r...
Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma [0.03%]
整合的基因组和肿瘤微环境分型可改善原发中枢神经系统淋巴瘤的风险分层
Xianggui Yuan,Qian Luo,Yurong Huang et al.
Xianggui Yuan et al.
Current prognostic models fail to capture the biological complexity of primary central nervous system lymphoma (PCNSL). We integrated whole-genome sequencing and multiplex immunofluorescence in 68 treatment-naïve patients to define four ge...
Intensive Induction in AML in the Era of Venetoclax: A Standing Count for "7 + 3"? [0.03%]
维奈克拉时代急性髓系白血病强化诱导治疗的"7+3"现状思考
Sudhir Tauro,Ayalew Tefferi
Sudhir Tauro
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis [0.03%]
高剂量美法仑联合自体干细胞移植治疗AL淀粉样变症长期疗效的影响因素分析
Maximilian J Steinhardt,Ute Hegenbart,Tamer Hellou et al.
Maximilian J Steinhardt et al.
High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively a...
Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents [0.03%]
血友病研究进展：从关节健康到FVIII指南以及再平衡药物的临床应用整合
Guy Young,Annette von Drygalski,Steven Pipe et al.
Guy Young et al.
Despite major advances in hemophilia care, many patients continue to experience breakthrough bleeding, progressive joint morbidity, inhibitor development, and substantial treatment burden. To help more individuals achieve active, unrestrict...